Back to Search
Start Over
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
- Source :
-
Diabetes Therapy . May2024, Vol. 15 Issue 5, p893-896. 4p. - Publication Year :
- 2024
-
Abstract
- The increasing occurrence of childhood overweight and obesity has been followed by a substantial increase in youth-onset type 2 diabetes (T2D). Pharmacological treatment options for youth-onset T2D remain limited, with a clear unmet need for additional oral agents. This summary of research reports on the efficacy and safety of empagliflozin and linagliptin on glycaemic control in children and adolescents aged 10–17 years with T2D in the randomised, double-blind, parallel group, phase 3 DINAMO trial. Empagliflozin provided a clinically relevant, statistically significant, and durable improvement in glycaemic control; however, linagliptin did not. The safety profile of both empagliflozin and linagliptin was comparable to those observed in studies in adults. These results suggest that empagliflozin could be a new oral therapy option for youth-onset T2D. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 18696953
- Volume :
- 15
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Diabetes Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 176842987
- Full Text :
- https://doi.org/10.1007/s13300-024-01555-0